Including patients in the decision-making process, the authors said, is an important component of patient-centered health care.
Formulary Watch
Latest News
All News
Advertisement
The monoclonal antibody had been given an emergency use authorization to treat COVID-19, but the recent spike in cases is driving a shortage in supply.
The move, effective July 15, was the result of a generic now being available.
A total of 16 lots have been recalled.
The therapy is expected to be available by early September.
Effective January 2023, the organization will switch from Express Scripts to CVS Caremark.
This vaccine protects against tick-borne encephalitis in people over the age of 1 year.
The multiple myeloma therapy now has a permanent J code under Medicare Part B.
Trials result show that Lyumjev compares favorably to Humalog.
All stakeholders together incur about $93.3 billion in costs for implementing, contesting, and navigating drug utilization management.
Advertisement
This is the first approval of generic version of Chantix, and it comes just weeks after a recall of the brand-name drug.
The potassium-lowering agent was associated with a 20% relative reduction in costs related to outpatient, inpatient, and emergency department visits.
Four products on the preferred list this year will be excluded next year.
The VA recommends against offering this agent to patients with Alzheimer’s dementia, mild or otherwise.
The program and proposed integrations could produce $15 million in savings annually.
The decision follows an advisory committee recommendation not to approve because of safety issues.
Libtayo also reduced the risk of death by 29% compared with chemotherapy alone.
A decision on the plaque psoriasis therapy is expected in the second quarter of 2022.
The graft-versus-host disease therapy has also been added to NCCN Guidelines.
Previously patients administered as two, 75-mg shots. Now they can inject a single 150-mg dose.
The bottles have a counterfeit foil seal or label and contain an incorrect number of tablets.
Current drug shortages based on FDA data, prepared by Formulary Watch.
The therapy for HIV-related pneumonia was exposed to cold weather during shipment.
The therapy can now be used for post-exposure prevention in people at high risk for progression to severe disease.
The PDUFA date has been set for December 4, 2021; FDA has designated this as a Priority Review.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
What employees may miss when they buy drugs directly online
2
Physicians may be the key for affordable healthcare
3
Prior authorization isn’t shrinking. Its savings are
4
Novo Nordisk's ziltivekimab falls short to reduce cardiovascular events in phase 3 trial
5